Green Cross HealthNZSE:GXH +1.01%63 EBITDA Margin % is 12.29% as of Mar. 2026, which is 32% above its 10-year median of 9.29. GuruFocus rates NZSE:GXH with a GF Score™ of 63/100 and a GF Value™ of NZ$1.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Green Cross Health ranks better than 51.58% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Green Cross Health's EBITDA for the
six
months ended in Mar. 2026 was NZ$34.4 Mil. Green Cross Health's Revenue for the
six
months ended in Mar. 2026 was NZ$280.1 Mil. Therefore, Green Cross Health's EBITDA margin for the quarter that ended in Mar. 2026 was 12.29%.
Green Cross Health (NZSE:GXH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Green Cross Health EBITDA Margin % Related Terms
Green Cross Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Green Cross Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Green Cross Health EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Green Cross Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Green Cross Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Green Cross Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Green Cross Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Green Cross Health (NZSE:GXH) has a EBITDA Margin % of 12.29% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Green Cross Health and its competitors. This is 32% above median its historical median of 9.29. Over the past decade, Green Cross Health's EBITDA Margin % has ranged from 6.67 to 11.05. According to the industry distribution chart, Green Cross Health ranks #322 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 48.4%.
Is Green Cross Health's EBITDA Margin % too high?
Green Cross Health's current EBITDA Margin % of 12.29% is 32% above median its 10-year median of 9.29. Over the past 10 years, this metric has ranged from a low of 6.67 to a high of 11.05. The Healthcare Providers & Services industry median EBITDA Margin % is 10.19. Green Cross Health's value of 12.29% is 20.6% above this industry median. Based on the distribution chart, Green Cross Health ranks #322 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Green Cross Health has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Green Cross Health's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Green Cross Health ranks #322 out of 665 companies for EBITDA Margin %. This puts Green Cross Health in the upper half of its industry. The industry median EBITDA Margin % is 10.19. Green Cross Health's value of 12.29% is 20.6% above this benchmark. Historically, Green Cross Health's own EBITDA Margin % has ranged from 6.67 to 11.05 over the past decade. While the company's 10-year median is 9.29 vs. the industry median of 10.19, Green Cross Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.19, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Green Cross Health's current EBITDA Margin % of 12.29% is 20.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Green Cross Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Green Cross Health's current EBITDA Margin % is 12.29%, which is 32% above median its own 10-year median of 9.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Green Cross Health stock overvalued right now?
Based on GuruFocus' analysis, Green Cross Health (NZSE:GXH) is currently considered Significantly Overvalued. The stock's GF Value™ is NZ$1.08, compared to a current price of NZ$2.00 — trading 85.2% above its estimated fair value. The current EBITDA Margin % is 12.29%, which is 32% above median its 10-year median of 9.29 and 20.6% above the Healthcare Providers & Services industry median of 10.19. Green Cross Health's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Green Cross Health (NZSE:GXH), the current EBITDA Margin % is 12.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Green Cross Health (NZSE:GXH) Overvalued in 2026?
Based on GuruFocus' analysis, Green Cross Health stock appears to be overvalued.
The current stock price of NZ$2.00 is trading 85.2% above its estimated GF Value™ of NZ$1.08.
GuruFocus considers Green Cross Health to be Significantly Overvalued.
Key valuation signals for NZSE:GXH:
EBITDA Margin %: 12.29% (32% above median its 10-year median of 9.29)
GF Value™: NZ$1.08 vs. price of NZ$2.00 (85.2% above fair value)
Industry Position: 20.6% above the Healthcare Providers & Services median (#322 of 665)
No single metric tells the full story. See the NZSE:GXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Green Cross Health Ltd is engaged in providing healthcare services in New Zealand. The reportable segments of the group are Pharmacy services and medical services. The majority of the revenue is generated from the Pharmacy services segment. The pharmacy services segment provides retail and dispensary services, and the medical services segment provides GP, nursing, and urgent care services. The majority of its revenue is generated from the pharmacy segment.
63GF Score
Get the complete analysis for NZSE:GXH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:GXH has been successfully added to your 
